Short answer
Wave Life Sciences Ltd. (WVE) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results announced for quarter ended September 30, 2026.
Wave Life Sciences Ltd. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results announced for quarter ended September 30, 2026
- Full earnings release furnished as Exhibit 99.1, providing the detailed financial and operating results investors need to assess performance
Item EX-99.1 · Exhibit EX-99.1
- Cash, equivalents and securities $431.0M, plus $12M GSK milestone, funding operations into 3Q 2028
- WVE-006 planning advances toward registrational trial, with one-year interim analysis targeting potential accelerated approval
- WVE-007 Phase 2a monotherapy and tirzepatide combination trials underway, with maintenance trial expected in 4Q 2026
- Revenue $13.2M vs $7.6M, while R&D rose to $53.8M and net loss widened to $61.9M
- GSK selected a SpiNA-based development candidate, with three additional collaboration programs advancing toward potential selection
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Wave Life Sciences Ltd. 8-K filings
Get the next WVE 8-K as it lands
Follow WVE for push alerts, or ask the research agent what this filing means.